Literature DB >> 23730416

Competitive but Not Allosteric mTOR Kinase Inhibition Enhances Tumor Cell Radiosensitivity.

Thomas J Hayman1, Tamalee Kramp, Jenna Kahn, Muhammad Jamal, Kevin Camphausen, Philip J Tofilon.   

Abstract

The mechanistic target of rapamycin (mTOR) is a critical kinase in the regulation of gene translation and has been suggested as a potential target for radiosensitization. The goal of this study was to compare the radiosensitizing activities of the allosteric mTOR inhibitor rapamycin with that of the competitive mTOR inhibitor PP242. On the basis of immunoblot analyses, whereas rapamycin only partially inhibited mTOR complex 1 (mTORC1) activity and had no effect on mTOR complex 2 (mTORC2), PP242 inhibited the activity of both mTOR-containing complexes. Irradiation alone had no effect on mTORC1 or mTORC2 activity. Clonogenic survival was used to define the effects of the mTOR inhibitors on in vitro radiosensitivity. In the two tumor cell lines evaluated, PP242 treatment 1 hour before irradiation increased radiosensitivity, whereas rapamycin had no effect. Addition of PP242 after irradiation also enhanced the radiosensitivity of both tumor lines. To investigate the mechanism of radiosensitization, the induction and repair of DNA double-strand breaks were evaluated according γH2AX foci. PP242 exposure did not influence the initial level of γH2AX foci after irradiation but did significantly delay the dispersal of radiation-induced γH2AX foci. In contrast to the tumor cell lines, the radiosensitivity of a normal human fibroblast cell line was not influenced by PP242. Finally, PP242 administration to mice bearing U251 xenografts enhanced radiation-induced tumor growth delay. These results indicate that in a preclinical tumor model PP242 enhances tumor cell radiosensitivity both in vitro and in vivo and suggest that this effect involves an inhibition of DNA repair.

Entities:  

Year:  2013        PMID: 23730416      PMCID: PMC3660805          DOI: 10.1593/tlo.13163

Source DB:  PubMed          Journal:  Transl Oncol        ISSN: 1936-5233            Impact factor:   4.243


  31 in total

1.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation.

Authors:  Andrew Y Choo; Sang-Oh Yoon; Sang Gyun Kim; Philippe P Roux; John Blenis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-27       Impact factor: 11.205

2.  Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.

Authors:  Haiyan Li; Jun Lin; Xiaokai Wang; Guangyu Yao; Liping Wang; Hang Zheng; Cuilan Yang; Chunhong Jia; Anling Liu; Xiaochun Bai
Journal:  Breast Cancer Res Treat       Date:  2012-04-04       Impact factor: 4.872

Review 3.  Rapamycin passes the torch: a new generation of mTOR inhibitors.

Authors:  Don Benjamin; Marco Colombi; Christoph Moroni; Michael N Hall
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

4.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Authors:  Christine M Chresta; Barry R Davies; Ian Hickson; Tom Harding; Sabina Cosulich; Susan E Critchlow; John P Vincent; Rebecca Ellston; Darren Jones; Patrizia Sini; Dominic James; Zoe Howard; Phillippa Dudley; Gareth Hughes; Lisa Smith; Sharon Maguire; Marc Hummersone; Karine Malagu; Keith Menear; Richard Jenkins; Matt Jacobsen; Graeme C M Smith; Sylvie Guichard; Martin Pass
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

5.  Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.

Authors:  Andrew C Hsieh; Davide Ruggero
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

Review 6.  PI3K and mTOR signaling pathways in cancer: new data on targeted therapies.

Authors:  Lise Willems; Jerome Tamburini; Nicolas Chapuis; Catherine Lacombe; Patrick Mayeux; Didier Bouscary
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

7.  Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma.

Authors:  Oleksandr Ekshyyan; Youhua Rong; Xiaohua Rong; Kavita M Pattani; Fleurette Abreo; Gloria Caldito; John Kai Siung Chang; Federico Ampil; Jonathan Glass; Cherie-Ann O Nathan
Journal:  Mol Cancer Ther       Date:  2009-07-22       Impact factor: 6.261

8.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

Review 9.  GammaH2AX and cancer.

Authors:  William M Bonner; Christophe E Redon; Jennifer S Dickey; Asako J Nakamura; Olga A Sedelnikova; Stéphanie Solier; Yves Pommier
Journal:  Nat Rev Cancer       Date:  2008-11-13       Impact factor: 60.716

10.  The translational landscape of mTOR signalling steers cancer initiation and metastasis.

Authors:  Andrew C Hsieh; Yi Liu; Merritt P Edlind; Nicholas T Ingolia; Matthew R Janes; Annie Sher; Evan Y Shi; Craig R Stumpf; Carly Christensen; Michael J Bonham; Shunyou Wang; Pingda Ren; Michael Martin; Katti Jessen; Morris E Feldman; Jonathan S Weissman; Kevan M Shokat; Christian Rommel; Davide Ruggero
Journal:  Nature       Date:  2012-02-22       Impact factor: 69.504

View more
  7 in total

1.  Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384.

Authors:  Andrew J Leiker; William DeGraff; Rajani Choudhuri; Anastasia L Sowers; Angela Thetford; John A Cook; Carter Van Waes; James B Mitchell
Journal:  Clin Cancer Res       Date:  2015-02-27       Impact factor: 12.531

2.  The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells.

Authors:  Jenna Kahn; Thomas J Hayman; Muhammad Jamal; Barbara H Rath; Tamalee Kramp; Kevin Camphausen; Philip J Tofilon
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

3.  Inhibition of the Translation Initiation Factor eIF4A Enhances Tumor Cell Radiosensitivity.

Authors:  Stacey L Lehman; Theresa Wechsler; Kayla Schwartz; Lauren E Brown; John A Porco; William G Devine; Jerry Pelletier; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Mol Cancer Ther       Date:  2022-09-06       Impact factor: 6.009

4.  Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Authors:  Iris Eke; Adeola Y Makinde; Molykutty J Aryankalayil; Veit Sandfort; Sanjeewani T Palayoor; Barbara H Rath; Lance Liotta; Mariaelena Pierobon; Emanuel F Petricoin; Matthew F Brown; Jayne M Stommel; Mansoor M Ahmed; C Norman Coleman
Journal:  Mol Cancer Ther       Date:  2017-08-11       Impact factor: 6.009

Review 5.  mTOR pathway in colorectal cancer: an update.

Authors:  Maria Giovanna Francipane; Eric Lagasse
Journal:  Oncotarget       Date:  2014-01-15

6.  The ATP-competitive mTOR inhibitor INK128 enhances in vitro and in vivo radiosensitivity of pancreatic carcinoma cells.

Authors:  Thomas J Hayman; Amy Wahba; Barbara H Rath; Heekyong Bae; Tamalee Kramp; Uma T Shankavaram; Kevin Camphausen; Philip J Tofilon
Journal:  Clin Cancer Res       Date:  2013-11-06       Impact factor: 13.801

7.  Myc coordinates transcription and translation to enhance transformation and suppress invasiveness.

Authors:  Ran Elkon; Fabricio Loayza-Puch; Gozde Korkmaz; Rui Lopes; Pieter C van Breugel; Onno B Bleijerveld; A F Maarten Altelaar; Elmar Wolf; Francesca Lorenzin; Martin Eilers; Reuven Agami
Journal:  EMBO Rep       Date:  2015-11-04       Impact factor: 8.807

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.